Recruiting
Not applicable
M-2018-334 in Hematological Malignancies
Condition(s) studied
Hematological Malignancies
Investigational drug(s) / intervention(s)
CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)
CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version): PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
Study summary
This is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.
Eligibility
Inclusion Criteria:
* Patients, between 18 years to 75 years of age, with high-risk hematological malignancy requiring an allogeneic hematopoietic stem cell transplantation (AlloHCT), but do not have an HLA-matched donor available
Exclusion Criteria:
* \<3 months after preceding autologous transplantation or prior AlloHCT
* History of neurological impairment (active seizures, severe peripheral neuropathy, signs of leukoencephalopathy, active CNS infection)
* Active fungal infections with radiological and clinical progression
* Liver function abnormalities with bilirubin \>2 mg/dL and elevation of transaminases higher than 400 U/L
* Chronic active viral hepatitis
* Cardiac dysfunction: adult patients ejection fraction \<50% on echocardiography
* Patients with uncontrolled, \>grade II hypertension (per Common Toxicity Criteria, CTC)
* Creatinine clearance \<60 mL/min/1.73m2
* Respiratory failure necessitating supplemental oxygen
* HIV infection
* Positive anti-donor HLA antibody
* Treatment with checkpoint inhibitors in the period between 3 months prior to and 3 months after transplantation
* Female patients who are pregnant or breast feeding, or adults of reproductive potential not willing to use an effective method of birth control during study treatment and for at least 12 months thereafter. Note: Women of childbearing potential must have a negative serum pregnancy test at study entry
* Concurrent severe or uncontrolled medical disease (e.g., uncontrolled diabetes, myocardial infarction within 6 months prior to the study) which by assessment of the treating physician could compromise participation in the study
* Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction).
* Patients unwilling or unable to comply with the protocol or unable to give informed consent
* Treatment with any investigational product within 4 weeks prior to study treatment
Primary outcome measure(s)
- Incidence of severe acute GVHD (aGVHD) till Day 100 — 100 days after haploidentical hematopoietic cell transplantation
Participants will be evaluated for the occurrence of aGVHD, grades III-IV in the first 100 days after transplantation and the time to occurrence of aGVHD, grades III-IV will be recorded. Severity of acute GVHD will be graded according to the CONSENSUS CRITERIA FOR GRADING OF ACUTE GVHD which has four Grades from Grade I to Grade IV. The higher the Score, the Worse the outcome.
Trial sites (1)
| Facility | City | Region | Status |
| City of Hope |
Duarte |
California |
Recruiting |
More Miltenyi Biomedicine GmbH trials in the USA
Other trials for the same condition